Capital Research Global Investors
WST icon

Capital Research Global Investors’s West Pharmaceutical WST Stock Holding History

Capital Research Global Investors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219M Buy
609,221
+5,210
+0.9% +$1.59M 0.03% 226
2026
Q1 		$151M Buy
+604,011
New +$150M 0.02% 273
2025
Q2 		– Sell
-390,678
Closed -$87.5M – 477
2025
Q1 		$87.5M Buy
390,678
+167,468
+75% +$46.2M 0.02% 298
2024
Q4 		$73.1M Buy
223,210
+63,017
+39% +$19.8M 0.02% 331
2024
Q3 		$48.1M Buy
+160,193
New +$49.1M 0.01% 343
2022
Q4 		– Sell
-494,732
Closed -$122M – 459
2022
Q3 		$122M Buy
494,732
+97
+0% +$29.6K 0.04% 245
2022
Q2 		$150M Buy
494,635
+155
+0% +$50.4K 0.05% 244
2022
Q1 		$203M Sell
494,480
-110,279
-18% -$43.2M 0.05% 237
2021
Q4 		$284M Sell
604,759
-56,636
-9% -$24.4M 0.06% 218
2021
Q3 		$281M Sell
661,395
-264
-0% -$111K 0.07% 217
2021
Q2 		$238M Buy
661,659
+802
+0.1% +$265K 0.06% 230
2021
Q1 		$186M Sell
660,857
-70,282
-10% -$20.1M 0.05% 253
2020
Q4 		$207M Sell
731,139
-149,910
-17% -$42.1M 0.05% 244
2020
Q3 		$242M Sell
881,049
-126,170
-13% -$33.4M 0.07% 198
2020
Q2 		$229M Sell
1,007,219
-290,319
-22% -$57M 0.07% 198
2020
Q1 		$198M Sell
1,297,538
-140,591
-10% -$21.6M 0.08% 189
2019
Q4 		$216M Buy
1,438,129
+1,216
+0.1% +$177K 0.06% 207
2019
Q3 		$204M Buy
1,436,913
+79
+0% +$10.9K 0.07% 206
2019
Q2 		$180M Buy
1,436,834
+967
+0.1% +$114K 0.06% 215
2019
Q1 		$158M Buy
1,435,867
+534,749
+59% +$55.6M 0.05% 228
2018
Q4 		$88.3M Buy
+901,118
New +$97.8M 0.03% 270

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Capital Research Global Investors's WST Position: Q2 2026 in Review

Capital Research Global Investors increased its West Pharmaceutical (WST) stake by 0.86% in Q2 2026, buying an estimated $1.59M and bringing the position to 609,221 shares worth $219M. The position accounts for 0.03% of the portfolio, ranked #226.

Capital Research Global Investors first reported a position in WST in Q4 2018 and has held it in 21 quarters since. The position peaked at $284M in Q4 2021. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Capital Research Global Investors held 609,221 shares of West Pharmaceutical worth $219M as of Q2 2026.
  • Capital Research Global Investors bought 5,210 West Pharmaceutical shares in Q2 2026, an estimated $1.59M.
  • West Pharmaceutical made up 0.03% of Capital Research Global Investors's portfolio in Q2 2026, its #226 holding.
  • Capital Research Global Investors first reported a position in West Pharmaceutical in Q4 2018 and has held it in 21 quarters since.
  • Capital Research Global Investors's West Pharmaceutical position peaked at $284M in Q4 2021.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.